NDAORALSOLUTION
Approved
Jan 2026
Lifecycle
Launch
Competitive Pressure
30/100
Clinical Trials
17
Data completeness
3/8 — Basic
QUIOFIC (folic acid) by Teva is clinical pharmacology folic acid acts on megaloblastic bone marrow to produce a normoblastic marrow. First approved in 2026.
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUIOFIC is an oral folic acid solution approved by the FDA on January 26, 2026, for the treatment of megaloblastic and macrocytic anemias caused by folic acid deficiency. The drug works by converting to tetrahydrofolic acid, a critical cofactor in nucleic acid synthesis that restores normal erythropoiesis and DNA synthesis in bone marrow. Folic acid is rapidly absorbed from the small intestine and reaches peak plasma levels within 1 hour of oral administration.
Launch
Early-stage launch product with moderate competitive pressure (30%) suggests active commercial buildout phase requiring full cross-functional team investment.
Mechanism of Action
CLINICAL PHARMACOLOGY Folic acid acts on megaloblastic bone marrow to produce a normoblastic marrow. In man, an exogenous source of folate is required for nucleoprotein synthesis and the maintenance of normal erythropoiesis. Folic acid is the precursor of tetrahydrofolic acid, which is involved as…
Worked on QUIOFIC at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.